Welcome to our dedicated page for Biovie SEC filings (Ticker: BIVI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BioVie, Inc. filings document a Nevada clinical-stage biopharmaceutical company with Nasdaq-listed Class A common stock and, in certain filings, warrants tied to its capital structure. Material-event reports cover securities offerings, underwriting agreements and issuances involving units, pre-funded units and warrants.
Proxy statements and related 8-K filings describe annual meeting voting matters, director elections, board appointments and amendments to the company’s omnibus equity incentive plan. Registration statement amendments provide formal disclosure for offering activity and financial-statement periods associated with BioVie’s development-stage operations.
On June 26, 2025, BioVie Inc. filed a Form 8-K announcing that its Board of Directors approved a one-for-ten (1:10) reverse stock split of the Company’s Class A common stock, as previously authorized by shareholders at the June 23, 2025 special meeting. The reverse split will become effective at 12:01 a.m. Eastern Time on July 7, 2025. Each block of ten issued and outstanding shares will automatically be reclassified into one share, with the $0.0001 par value unchanged.
The total number of authorized shares of common stock remains the same. All outstanding stock options, restricted stock units, and warrants will be adjusted proportionally: the number of underlying shares will be divided by ten and the corresponding exercise prices increased by the same factor. No fractional shares will be issued; shareholders otherwise entitled to a fraction will receive one whole post-split share.
West Coast Stock Transfer, Inc. will act as exchange agent, and shareholders holding shares in book-entry or “street name” are not required to take any action. Trading will continue on the Nasdaq Capital Market under the symbol “BIVI” on a split-adjusted basis beginning July 7, 2025. The Company’s common stock will adopt a new CUSIP number: 09074F504.
This event is reported under Item 3.03, constituting a material modification to the rights of security holders.
BioVie held a Special Meeting of stockholders on June 23, 2025, with 10,971,031 shares represented out of 18,570,726 outstanding shares of Class A common stock. Two key proposals were voted on:
Proposal 1: Reverse Stock Split Authorization The stockholders approved granting the Board authority to implement a reverse stock split at a ratio between 1-for-5 and 1-for-10, to be executed within one year. The voting results showed:
- For: 8,664,435 shares (79%)
- Against: 2,200,874 shares
- Abstain: 105,722 shares
Proposal 2: Meeting Adjournment Authority Shareholders approved discretionary authority to adjourn the meeting if needed to gather more proxies, with:
- For: 8,788,143 shares (80%)
- Against: 2,033,834 shares
- Abstain: 149,054 shares